-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2022-502798-40-00
5
2017-07-31
Patients with resected colon carcinoma
-
2024-514841-12-00
5
2015-10-27
To determine whether the addition of palbociclib to adjuvant endocrine
-
2023-509136-25-00
5
2015-07-16
Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
-
2024-517190-24-00
4
2025-09-16
Peritoneal Cancer
-
2026-525342-29-00
2
2026-03-16
Transthyretin amyloidosis
-
2025-522574-36-00
2
2025-11-04
Primary and secondary hypertension, and heart failure
-
2025-521029-34-00
4
2025-09-18
Patients with overt hepatic encephalopathy (OHE) and acute decompensat
-
2025-522331-34-00
3
2025-09-15
locally advanced or metastatic ER+/HER2- breast cancer
-
2025-521924-31-00
3
2025-08-20
locally advanced or metastatic HR+/HER2- breast cancer
-
2025-520558-12-00
3
2025-07-09
Clonal hematopoiesis
-
2024-520126-11-00
3
2025-03-14
Heart Failure
-
2022-502878-16-00
5
2025-01-23
Acute ischemic strokes with incomplete reperfusion
-
2024-514166-40-00
2
2024-12-16
Transthyretin amyloidosis
-
2024-515421-28-00
1
2024-11-28
RSV (Respiratory Syncytial Virus)
-
2024-512651-20-00
4
2024-11-20
Fetal and Neonatal Alloimmune Thrombocytopenia due to Human Platelet A
-
2024-516907-18-00
3
2024-11-20
Small cell lung cancer, Castration-resistant prostate cancer, Follicul
-
2024-517797-14-00
3
2024-11-19
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
-
2023-509197-35-00
5
2024-10-17
Thyroid Eye Disease (TED)
-
2024-514169-21-00
3
2024-10-11
ER+/HER2- Breast Cancer
-
2023-507354-32-00
1
2024-09-09
Ulcerative Colitis
-
2024-513467-47-00
1
2024-08-08
clonal hematopoiesis
-
2023-507117-10-00
3
2024-07-09
Complicated urinary tract infection including pyelonephritis